Filing Flows › Comparisons › AUTL vs AGEN
Autolus Therapeutics vs Agenus: AUTL and AGEN compared
Autolus Therapeutics is the larger company: $45.7M of revenue in its latest quarter (Q2 2026) against $31.5M for Agenus (Q3 2026). Autolus Therapeutics is growing faster (+118% against +4% a year earlier). Agenus is more profitable, with an operating margin of 36.2% against -95.9%.
Where the money goes: AUTL and AGEN
Autolus Therapeutics (AUTL) · Q2 2026
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
Agenus (AGEN) · Q3 2026
Agenus, Q3 2026: revenue $31.5M (+4% year over year), operating margin 36.2%, net earnings $1.5M, operating cash flow −$20.1M. The chart follows the revenue to costs, profit and cash.
| Autolus Therapeutics (AUTL) | Agenus (AGEN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $45.7M | $31.5M |
| Revenue growth, Y/Y | +118% | +4% |
| Operating margin | -95.9% | 36.2% |
| Net earnings | −$39.1M | $1.5M |
| Net margin | -85.6% | 4.8% |
| Operating cash flow | −$25.1M | −$20.1M |
Where the revenue comes from
Autolus Therapeutics
- Product revenue, net: $45.7M (100%)
- License revenue: $17K (0%)
Agenus
- Non Cash Royalty Revenue Related to the Sale of Future Royalties: $25.4M (81%)
- Pre Commercial Product Revenue: $6.1M (19%)
Questions
Which is bigger, Autolus Therapeutics or Agenus?
Autolus Therapeutics is the larger company: $45.7M of revenue in its latest quarter (Q2 2026) against $31.5M for Agenus (Q3 2026).
Is Autolus Therapeutics or Agenus growing faster?
Autolus Therapeutics is growing faster (+118% against +4% a year earlier).
Which is more profitable, Autolus Therapeutics or Agenus?
Agenus is more profitable, with an operating margin of 36.2% against -95.9%.
More: Autolus Therapeutics earnings · how Autolus Therapeutics makes money · Agenus earnings · how Agenus makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.